Skip to main content

Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start

The Alzheimer's drug Leqembi from Biogen and Eisai is seeing a slow launch, but demand is rising. Meanwhile, headsets are making some users nauseous.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.